



July 11, 2016

Acura Pharmaceuticals to Host Webcast on July 14, 2016 to Discuss Additional Data From Study AP-LTX-400

Data Supports Effectiveness of LIMITX(TM) Technology to Address Oral Opioid Abuse

PALATINE, IL -- (Marketwired) -- 07/11/16 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating [abuse deterrent drugs](#), today announced that the Company will host a conference call and webcast on Thursday, July 14, 2016 at 8:30 a.m. ET to discuss additional data from Study AP-LTX-400, a pharmacokinetic study in healthy subjects of hydromorphone hydrochloride immediate-release tablets using the Company's new LIMITX™ oral abuse deterrent technology. This information to be presented will be a more detailed analysis of the Study's topline results previously announced.

The presentation will be webcast live and may be accessed by visiting the Company's website, Acurapharm.com and selecting the "News and Events" option under the "Investors" tab. For those wishing to listen only you may dial **1-888-504-7963** with passcode **8485122**. A replay of the webcast will be available for 60 days on the Acura website.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

OXAYDO® (oxycodone HCl immediate-release tablets) which incorporates the AVERSION Technology, is FDA approved and marketed in the U.S. by our partner Egalet Corporation.

Acura markets NEXAFED® and NEXAFED® Sinus, which are pseudoephedrine containing products that utilize the IMPEDE Technology.

Contact:
for Acura Investor Relations
[Email contact](#)

847-705-7709

Renmark Financial Communications Inc.
Robert Thaemlitz
[Email contact](#)

(416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com

Source: Acura Pharmaceuticals, Inc.

News Provided by Acquire Media